Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

Summary

The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.

Timeline

Start

2021-01-12

Primary completion

2021-12-15

Completion

2022-02-10

Drugs

Indications